Clinical trials are urgently needed for PSP and CBD. Dr. Maura Malpetti and her team at the University of Cambridge have identified chronic brain inflammation as a key contributor to disease progression, and are developing a blood test for inflammation that will help track the effectiveness of clinical trials and treatments, thus accelerating the development of more clinical trials. 

Dr. Malpetti spoke to us about the mysteries of brain inflammation, its role in PSP and CBD and how this research could revolutionize the way we diagnose, treat and understand these conditions. 

With support from CurePSP’s Pipeline grant program, which provides seed funding to support translational projects focusing on new therapeutics and biomarkers for tauopathies, Dr. Malpetti will be developing an innovative blood test to measure patterns of inflammation in people living with PSP and CBD. Read more about her study here. 

Tauopathies remain some of the most mysterious diseases in science, with no current treatments available for conditions like PSP, CBD and MSA. Dr. Kathryn Bowles and her team at the University of Edinburgh are studying mutations in the MAPT gene, a known driver of tauopathies, and how these mutations alter mitochondrial function in brain cells. Using cutting-edge 3D organoid models, or “mini-brains” created from patient blood cells, they aim to unravel the complex relationship between tau and neuron survival. Dr. Bowles shares how understanding these mechanisms could open the door to novel treatments for primary tauopathies and prevent neuron death in these diseases. 

With support from CurePSP’s Pathway grant program, which provides seed funding to support projects studying the fundamental neurobiology of PSP and CBD, Dr. Bowles hopes to develop new treatments to prevent these mutations. Read more about her study here.

Anyone affected by PSP, CBD or MSA knows the importance of advocating for yourself. After years of limited awareness, 2024 marked a turning point for PSP, CBD and MSA advocacy with the historic passage of the National Plan to End Parkinson’s Act. From Congresswoman Jennifer Wexton’s announcement of her PSP diagnosis to the numerous messages that our community members sent to their local representatives, several factors emerged to create the momentum necessary for this landmark moment. 

To reflect on how we got here and what comes next, I spoke with two of CurePSP’s most dedicated advocates: Jessica Shurer, director of clinical affairs and advocacy, and Julie Balasille, longtime volunteer and macro social worker with extensive professional experience in legislative and community advocacy in both the US and Canada. We discussed strategies for empowering the community, lessons from previous legislative successes, the influence of Rep. Wexton’s advocacy, highlights from this year’s efforts and key moments to look forward to in the future.

For the latest updates and ways to get involved, visit CurePSP’s advocacy page here.

Eugenia Aguirre found herself at a crossroads when she was diagnosed with corticobasal degeneration (CBD). Overwhelmed by the rapid lifestyle changes that accompanied her diagnosis, she chose to make the most of every day and fight as hard as she could. Living alone meant managing the disease was a lonely and daunting journey, until she connected with the Flying Solo Support Group, where she met a group of similarly independent individuals. The group offered a space where members could be honest and discuss important topics like social anxiety, coping with symptoms and how to feel prepared as one’s situation changes, fostering a sense of hope and resilience. I spoke to Eugenia and the two support group leaders, Adriana Gonzalez and Diane Breslow, on how the members of Flying Solo are empowering each other to live their own way. 

Learn more about Flying Solo here. 

The causes of progressive supranuclear palsy (PSP) remain one of the biggest mysteries of the disease. Dr. Jessica Rexach and her team at UCLA have been scouring sequencing data from over 10,000 individuals searching for clues in the DNA that could explain how changes in the immune system might influence why some individuals develop the disease. Dr. Rexach spoke to me about the crucial role that the immune system seems to play in disease progression, the intriguing similarities and differences between PSP and Alzheimer's, and what can be learned from the success of immune system therapeutics in cancer and autoimmune disease.
 
Supported by CurePSP’s Pathway Grant Program, Dr. Rexach’s project aims to piece together a picture of the altered messengers of the immune system that could pave the way for future immune-based therapies. Read more about her study here. 

Caring for a loved one is a grueling journey that no care partner would ever turn away from. Bob Weide did not know what to expect when he started noticing little differences in his wife Linda’s balance and speech. He could not have known that these were the first symptoms of progressive supranuclear palsy (PSP), an uncompromising disease that requires seemingly endless amounts of patience and grace. Bob spoke to me almost two years after Linda’s death on the lessons he learned as a care partner, humor as a coping mechanism and the importance of grieving daily. 

Read Bob’s full tribute to Linda here. 

Meet Oscar and learn more about this original series that will spotlight stories and insights from the CurePSP community and discuss the latest in cutting-edge research.